Madrigal reports sales boost for Rezdiffra while welcoming Novo to MASH market
5th November 2025 Uncategorised 0Madrigal’s Rezdiffra generated sales of $287 million in the third quarter for a 35% sequential jump from Q2. In just its fifth full quarter on the market, the world’s first treatment for metabolic dysfunction-associated steatohepatitis (MASH) is now annualizing at more than $1 billion.
More: Madrigal reports sales boost for Rezdiffra while welcoming Novo to MASH market
Source: fierce